Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans

Science Translational Medicine

Volumn 5, Issue 209, 2013, Pages

  Finan, Brian ^a,b,c   Ma, Tao ^c,d   Ottaway, Nickki ^e   Müller, Timo D ^a,b   Habegger, Kirk M ^e   Heppner, Kristy M ^e   Kirchner, Henriette ^f   Holland, Jenna ^e   Hembree, Jazzminn ^e   Raver, Christine ^e   Lockie, Sarah H ^g   Smiley, David L ^c   Gelfanov, Vasily ^c   Yang, Bin ^c,h   Hofmann, Susanna ^b   Bruemmer, Dennis ⁱ   Drucker, Daniel J ^j   Pfluger, Paul T ^a,b,e   Perez Tilve, Diego ^e   Gidda, Jaswant ^h   Vignati, Louis ^h   Zhang, Lianshan ^h   Hauptman, Jonathan B ^k   Lau, Michele ^k   Brecheisen, Mathieu ^k   Uhles, Sabine ^k   Riboulet, William ^k   Hainaut, Emmanuelle ^k   Sebokova, Elena ^k   Conde Knape, Karin ^k   Konkar, Anish ^k   DiMarchi, Richard D ^c   Tschöp, Matthias H ^a,b,e   more..

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INDIANA UNIVERSITY   (United States)

^d Beijing Hanmi Pharmaceutical   (China)

^e Metabolic Disease Institute   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

^g MONASH UNIVERSITY   (Australia)

^h Marcadia Biotech   (United States)

ⁱ UNIVERSITY OF KENTUCKY   (United States)

^j MOUNT SINAI HOSPITAL   (Canada)

^k F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CHOLESTEROL; EXENDIN 4; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON RECEPTOR; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; HEMOGLOBIN A1C; HORMONE RECEPTOR; INCRETIN; INSULIN; KETONE; LIRAGLUTIDE; MACROGOL; PARACETAMOL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNIMOLECULAR DUAL INCRETIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DYSLIPIDEMIA; ENERGY BALANCE; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL OBESITY; FAT MASS; FEMALE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESISTANCE; MACACA FASCICULARIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE BLIND PROCEDURE; STOMACH EMPTYING; VOMITING; WEIGHT REDUCTION; YOUNG ADULT;

ACYLATION; ADOLESCENT; ADULT; AGED; ANIMALS; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HAPLORHINI; HUMANS; HYPERGLYCEMIA; INCRETINS; INSULIN; MALE; MICE; MIDDLE AGED; PEPTIDES; RATS; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; RODENTIA; TREATMENT OUTCOME; VENOMS; WEIGHT LOSS; YOUNG ADULT;

EID: 84890043525     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007218     Document Type: Article

References (42)

1. J. G. Barrera, D. A. Sandoval, D. A. D'Alessio, R. J. Seeley, GLP-1 and energy balance: An integrated model of short-term and long-term control. Nat. Rev. Endocrinol. 7, 507-516 (2011).
2. D. J. Drucker, The biology of incretin hormones. Cell Metab. 3, 153-165 (2006).
3. A. Astrup, S. Rössner, L. Van Gaal, A. Rissanen, L. Niskanen, M. Al Hakim, J. Madsen, M. F. Rasmussen, M. E. Lean; NN8022-1807 Study Group, Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 374, 1606-1616 (2009).
4. R. E. Amori, J. Lau, A. G. Pittas, Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 298, 194-206 (2007).
5. S. J. Kim, C. Nian, C. H. McIntosh, Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMPactivated protein kinase cascade. J. Biol. Chem. 282, 8557-8567 (2007).
6. K. Miyawaki, Y. Yamada, H. Yano, H. Niwa, N. Ban, Y. Ihara, A. Kubota, S. Fujimoto, M. Kajikawa, A. Kuroe, K. Tsuda, H. Hashimoto, T. Yamashita, T. Jomori, F. Tashiro, J. Miyazaki, Y. Seino, Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96, 14843-14847 (1999).
7. K. Miyawaki, Y. Yamada, N. Ban, Y. Ihara, K. Tsukiyama, H. Zhou, S. Fujimoto, A. Oku, K. Tsuda, S. Toyokuni, H. Hiai,W. Mizunoya, T. Fushiki, J. J. Holst, M. Makino, A. Tashita, Y. Kobara, Y. Tsubamoto, T. Jinnouchi, T. Jomori, Y. Seino, Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8, 738-742 (2002).
8. M. C. Althage, E. L. Ford, S. Wang, P. Tso, K. S. Polonsky, B. M. Wice, Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J. Biol. Chem. 283, 18365-18376 (2008).
9. V. A. Gault, F. P. O'Harte, P. Harriott, P. R. Flatt, Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 290, 1420-1426 (2002).
10. V. A. Gault, F. P. O'Harte, P. Harriott, M. H. Mooney, B. D. Green, P. R. Flatt, Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: Evidence that GIP is the major physiological incretin. Diabetologia 46, 222-230 (2003).
11. P. L. McClean, N. Irwin, R. S. Cassidy, J. J. Holst, V. A. Gault, P. R. Flatt, GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Aml J. Physiol. Endocrinol. Metab. 293, E1746-E1755 (2007).
12. M. A. Nauck, M. M. Heimesaat, C. Orskov, J. J. Holst, R. Ebert, W. Creutzfeldt, Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91, 301-307 (1993).
13. T. Vilsbøll, F. K. Knop, T. Krarup, A. Johansen, S. Madsbad, S. Larsen, T. Hansen, O. Pedersen, J. J. Holst, The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-Regardless of etiology and phenotype. J. Clin. Endocrinol. Metab. 88, 4897-4903 (2003).
14. S. J. Kim, C. Nian, S. Karunakaran, S. M. Clee, C. M. Isales, C. H. McIntosh, GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 7, e40156 (2012).
15. S. Renner, C. Fehlings, N. Herbach, A. Hofmann, D. C. von Waldthausen, B. Kessler, K. Ulrichs, I. Chodnevskaja, V. Moskalenko, W. Amselgruber, B. Göke, A. Pfeifer, R. Wanke, E. Wolf, Glucose intolerance and reduced proliferation of pancreatic b-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes 59, 1228-1238 (2010).
16. T. D. Müller, L. M. Sullivan, K. Habegger, C. X. Yi, D. Kabra, E. Grant, N. Ottaway, R. Krishna, J. Holland, J. Hembree, D. Perez-Tilve, P. T. Pfluger, M. J. DeGuzman, M. E. Siladi, V. S. Kraynov, D. W. Axelrod, R. DiMarchi, J. K. Pinkstaff, M. H. Tschöp, Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J. Pept. Sci. 18, 383-393 (2012).
17. N. M. Neary, C. J. Small, M. R. Druce, A. J. Park, S. M. Ellis, N. M. Semjonous, C. L. Dakin, K. Filipsson, F. Wang, A. S. Kent, G. S. Frost, M. A. Ghatei, S. R. Bloom, Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146, 5120-5127 (2005).
18. T. Talsania, Y. Anini, S. Siu, D. J. Drucker, P. L. Brubaker, Peripheral exendin-4 and peptide YY3-36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 146, 3748-3756 (2005).
19. N. Mentis, I. Vardarli, L. D. Köthe, J. J. Holst, C. F. Deacon,M. Theodorakis, J. J. Meier,M. A. Nauck, GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 60, 1270-1276 (2011).
20. J. W. Day, N. Ottaway, J. T. Patterson, V. Gelfanov, D. Smiley, J. Gidda, H. Findeisen, D. Bruemmer, D. J. Drucker, N. Chaudhary, J. Holland, J. Hembree, W. Abplanalp, E. Grant, J. Ruehl, H. Wilson, H. Kirchner, S. H. Lockie, S. Hofmann, S. C. Woods, R. Nogueiras, P. T. Pfluger, D. Perez-Tilve, R. DiMarchi, M. H. Tschöp, A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5, 749-757 (2009).
21. J. Wu, P. Boström, L. M. Sparks, L. Ye, J. H. Choi, A. H. Giang, M. Khandekar, K. A. Virtanen, P. Nuutila, G. Schaart, K. Huang, H. Tu, W. D. van Marken Lichtenbelt, J. Hoeks, S. Enerbäck, P. Schrauwen, B. M. Spiegelman, Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell 150, 366-376 (2012).
22. T. Hansotia, L. L. Baggio, D. Delmeire, S. A. Hinke, Y. Yamada, K. Tsukiyama, Y. Seino, J. J. Holst, F. Schuit, D. J. Drucker, Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53, 1326-1335 (2004).
23. K. M. Habegger, K. Stemmer, C. Cheng, T. D. Müller, K. M. Heppner, N. Ottaway, J. Holland, J. L. Hembree, D. Smiley, V. Gelfanov, R. Krishna, A. M. Arafat, A. Konkar, S. Belli, M. Kapps, S. C. Woods, S. M. Hofmann, D. D'Alessio, P. T. Pfluger, D. Perez-Tilve, R. J. Seeley, M. Konishi, N. Itoh, A. Kharitonenkov, J. Spranger, R. D. DiMarchi, M. H. Tschöp, Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62, 1453-1463 (2013).
24. D. Russell-Jones, S. Gough, Recent advances in incretin-based therapies. Clin. Endocrinol. 77, 489-499 (2012).
25. B. Finan, B. Yang, N. Ottaway, K. Stemmer, T. D. Müller, C. X. Yi, K. Habegger, S. C. Schriever, C. García-Cáceres, D. G. Kabra, J. Hembree, J. Holland, C. Raver, R. J. Seeley,W. Hans, M. Irmler, J. Beckers, M. H. de Angelis, J. P. Tiano, F. Mauvais-Jarvis, D. Perez-Tilve, P. Pfluger, L. Zhang, V. Gelfanov, R. D. DiMarchi, M. H. Tschöp, Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18, 1847-1856 (2012).
26. J. W. Day, P. Li, J. T. Patterson, J. Chabenne, M. D. Chabenne, V. M. Gelfanov, R. D. Dimarchi, Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action. J. Pept. Sci. 17, 218-225 (2011).
27. K. L. Edwards, M. Stapleton, J. Weis, B. K. Irons, An update in incretin-based therapy: A focus on glucagon-like peptide-1 receptor agonists. Diabetes Technol. Ther. 14, 951-967 (2012).
28. B. Gier, A. V. Matveyenko, D. Kirakossian, D. Dawson, S. M. Dry, P. C. Butler, Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the KrasG12D mouse model. Diabetes 61, 1250-1262 (2012).
29. P. C. Butler, M. Elashoff, R. Elashoff, E. A. Gale, A critical analysis of the clinical use of incretinbased therapies: Are the GLP-1 therapies safe? Diabetes Care 36, 2118-2125 (2013).
30. M. A. Nauck, O. Baranov, R. A. Ritzel, J. J. Meier, Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia 56, 1878-1883 (2013).
31. R. N. Kulkarni, GIP: No longer the neglected incretin twin? Sci. Transl. Med. 2, 49ps47 (2010).
32. C. H. McIntosh, S. Widenmaier, S. J. Kim, Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide; GIP). Vitam. Horm. 80, 409-471 (2009).
33. S. J. Kim, C. Nian, C. H. McIntosh, Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J. Biol. Chem. 282, 34139-34147 (2007).
34. S. J. Kim, C. Nian, C. H. McIntosh, GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. J. Lipid Res. 51, 3145-3157 (2010).
35. T. Hansotia, A. Maida, G. Flock, Y. Yamada, K. Tsukiyama, Y. Seino, D. J. Drucker, Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J. Clin. Invest. 117, 143-152 (2007).
36. S. B. Widenmaier, S. J. Kim, G. K. Yang, T. De Los Reyes, C. Nian, A. Asadi, Y. Seino, T. J. Kieffer, Y. N. Kwok, C. H. McIntosh, A GIP receptor agonist exhibits b-cell anti-apoptotic actions in rat models of diabetes resulting in improved b-cell function and glycemic control. PLoS One 5, e9590 (2010).
37. L. A. Scrocchi, D. J. Drucker, Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor-/- mice. Endocrinology 139, 3127-3132 (1998).
38. E. Faivre, A. Hamilton, C. Hölscher, Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. Eur. J. Pharmacol. 674, 294-306 (2012).
39. D. Schelshorn, F. Joly, S. Mutel, C. Hampe, B. Breton, V. Mutel, R. Lütjens, Lateral allosterism in the glucagon receptor family: Glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Mol. Pharmacol. 81, 309-318 (2012).
40. C. W. Chia, O. D. Carlson, W. Kim, Y. K. Shin, C. P. Charles, H. S. Kim, D. L. Melvin, J. M. Egan, Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58, 1342-1349 (2009).
41. A. Bénardeau, P. Verry, E. A. Atzpodien, J. M. Funk, M. Meyer, J. Mizrahi, M. Winter, M. B. Wright, S. Uhles, E. Sebokova, Effects of the dual PPAR-a/g agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat. Diabetes Obes. Metab. 15, 164-174 (2013).
42. S. Uhles, H. Wang, A. Bénardeau, M. Prummer, M. Brecheisen, S. Sewing, L. Tobalina, D. Bosco, C. B. Wollheim, C. Migliorini, E. Sebokova, Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic b-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo. Diabetes Obes. Metab. 13, 326-336 (2011).